Dominari Holdings Inc. (NASDAQ:DOMH - Get Free Report) dropped 9.1% during mid-day trading on Friday . The stock traded as low as $5.59 and last traded at $5.68. Approximately 797,549 shares were traded during trading, an increase of 197% from the average daily volume of 268,978 shares. The stock had previously closed at $6.25.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen downgraded Dominari from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd.
Check Out Our Latest Analysis on DOMH
Dominari Trading Down 9.1%
The firm has a market capitalization of $83.16 million, a PE ratio of -1.26 and a beta of 0.57. The business has a 50 day moving average price of $4.98 and a 200-day moving average price of $4.27.
Dominari (NASDAQ:DOMH - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $0.20 earnings per share (EPS) for the quarter. The business had revenue of $6.56 million during the quarter. Dominari had a negative return on equity of 91.67% and a negative net margin of 167.73%.
Hedge Funds Weigh In On Dominari
An institutional investor recently bought a new position in Dominari stock. PFG Investments LLC bought a new position in shares of Dominari Holdings Inc. (NASDAQ:DOMH - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 141,508 shares of the company's stock, valued at approximately $566,000. PFG Investments LLC owned approximately 1.30% of Dominari at the end of the most recent quarter. 42.48% of the stock is currently owned by institutional investors.
Dominari Company Profile
(
Get Free Report)
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dominari, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dominari wasn't on the list.
While Dominari currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
